Medico Remedies Q2 FY27 Results Board Meeting Set for November 9

Medico Remedies Limited will consider and approve its unaudited Q2 FY27 results for the quarter ended September 30, 2026, at a board meeting on November 9, following ₹69.40 crore in standalone sales in Q1 FY27, up 81.4% year-on-year. The company has not yet filed its September-quarter figures.

When will Medico Remedies announce Q2 FY27 results?

Medico Remedies Limited is scheduled to hold its board meeting on Monday, November 9, 2026, to consider and approve unaudited financial results for the July-September 2026 quarter. The company informed the National Stock Exchange on November 3 that the agenda also includes the limited review report and other matters permitted under applicable rules.

The filing is an advance notice of the board meeting rather than an earnings announcement. As a result, there are no reported sales, profit, margin, or operational figures for Q2 FY27 in the available information. The results are expected to reach the exchange after the board approves them.

The September quarter ended 40 days before the scheduled meeting date. For comparison, Medico Remedies filed its Q1 FY27 results on August 13, 2026, or 44 days after the June-quarter end. The timing provides investors with a defined date for the next official update but does not establish an outcome for the quarter.

What did Medico Remedies report in the June 2026 quarter?

Medico Remedies reported standalone sales of ₹69.40 crore in the quarter ended June 2026, compared with ₹38.25 crore in the corresponding quarter a year earlier. This represented year-on-year sales growth of about 81.4%, while sales were also above ₹56.81 crore recorded in the March 2026 quarter.

Net profit for Q1 FY27 was reported at about ₹2 crore in the supplied quarterly summary. That summary showed profit growth of 38.7% year-on-year, while profit was lower sequentially. Gross profit was ₹4.06 crore and operating profit was ₹3.30 crore in the June quarter, compared with ₹9.12 crore and ₹7.15 crore, respectively, in the preceding March quarter.

The quarterly data show that sales increased sharply from the year-earlier base, while profitability measures moved differently on a sequential basis. The Q2 FY27 filing will be the next disclosed data point for assessing whether the June-quarter revenue momentum and profit trend continued through September.

How has Medico Remedies performed over the past year?

Medico Remedies reported standalone sales of ₹206.38 crore for the financial year ended March 2026, up 36.7% from ₹150.94 crore in FY25. Profit after tax rose 30.0% to ₹13.12 crore from ₹10.09 crore over the same period.

For the March 2026 quarter, standalone net profit rose 35.0% year-on-year to ₹5.86 crore, while sales increased 37.6% to ₹56.81 crore. These figures preceded the higher ₹69.40 crore sales reported in the June 2026 quarter.

The company’s FY26 operating profit was ₹17.03 crore, against ₹15.00 crore in FY25. However, operating profit margin was 8.25% in FY26, compared with 9.94% a year earlier. This indicates that annual operating profit grew in absolute terms while the margin was lower than in the preceding year.

Why does the November 9 board meeting matter to investors?

The November 9 meeting matters because it will provide Medico Remedies' first official financial update for the September 2026 quarter. The prior quarter delivered an 81.4% year-on-year increase in sales, making the revenue comparison a key factual reference point when the company files Q2 results.

Investors will also be able to compare the September-quarter figures with the June-quarter gross profit of ₹4.06 crore and operating profit of ₹3.30 crore. The available board-meeting notice does not provide guidance, management commentary, or an expected range for the Q2 numbers, so conclusions on financial performance should await the exchange filing.

The event is procedural, but it is relevant for market participants because it fixes the date on which the board will review the unaudited accounts and limited review report. The company’s stated market value in the supplied data is ₹149 crore, though no share-price movement linked to the notice has been provided.

What should readers look for in the Q2 FY27 filing?

Readers should look for reported standalone sales, net profit, gross profit, operating profit, and the corresponding year-on-year comparisons when Medico Remedies files its Q2 FY27 results. These disclosed figures will allow a direct assessment against Q1 FY27 sales of ₹69.40 crore and Q2 FY26 sales of ₹52.64 crore, if the same presentation is provided.

The filing may also contain the limited review report that is listed on the board-meeting agenda. The notice itself does not disclose business developments, dividend proposals, capital actions, or other financial decisions. Therefore, only the eventual approved results and accompanying exchange disclosures can confirm the quarter’s performance.

Conclusion

Medico Remedies has scheduled its Q2 FY27 results board meeting for November 9, with the September-quarter financials still pending. The most recent disclosed quarter showed sales of ₹69.40 crore, up 81.4% year-on-year, while FY26 sales and profit after tax rose to ₹206.38 crore and ₹13.12 crore, respectively.

The next item to watch is the exchange filing following the November 9 board meeting, including the unaudited results and limited review report. That disclosure will provide the confirmed Q2 FY27 sales, profit, and operating metrics needed to compare the September quarter with the June 2026 and year-earlier periods.